Cabaletta Bio: EULAR Sell-Off Creates Entry, But PC-Free Durability Remains Unproven

What happened

Cabaletta presented promising EULAR data for rese-cel, but the market sold off, creating what some see as a buying opportunity at $2.90. The article highlights a de-risked platform, strong safety, and a recent $150M raise with top-tier investor participation. However, the DeepValue report underscores that the preconditioning-free data remains low-N, with only 2/4 drug-free responses at 6 months, and the company has a going-concern warning. Automated manufacturing via Cellares is encouraging but still in early stages, with no formal comparability. The next 6-12 months are critical to confirm durability beyond 9 months and manufacturing scalability.

Implication

Investors should remain on the sidelines until the company demonstrates durable drug-free responses past 9 months in larger PC-free cohorts and provides clear comparability data for automated manufacturing. The recent sell-off after EULAR may be overdone, but the thesis is not yet de-risked. A reassessment window of 6-12 months is appropriate, with an attractive entry near $3.00. Dilution risk remains high due to the authorized share increase and ongoing ATM usage.

Thesis delta

The prior thesis (March 2026) rated WAIT with a conviction of 3.5, valuing the stock at $3.80. The new article suggests the post-EULAR sell-off creates a compelling entry at $2.90, but the fundamental risk of unproven PC-free durability remains unchanged. The delta is that the stock is cheaper, but the data required to upgrade the thesis has not yet materialized.